Impact of clinical pharmacist intervention on the use of oral anti clotting agents

Abstract

Anticoagulants and antiplatelet agents are drugs that reduce blood flow to the arteries, veins, or heart. Blood clots can block the flow of blood to your heart and cause heart disease. Effective treatment improves patient adherence, citing fewer cases of treatment failure and bleeding problems. To study the impact of clinical pharmacist in anti-clotting therapy. Testing information for anticlotting treatment, to assess adherence of a patient to therapy, to assess drug interactions and adverse effects in therapy by pharmacist intervention. Expected randomized trial - a control intervention study was conducted for a period of 6 months in the department of general medicine, cardiology, and neurology at a regular public hospital in Guntur. A total of 187 patients with anti-clotting treatment were randomly assigned and analyzed information on a list of questions about anti-clotting treatment. Information was assessed in both groups before and after the study and the mean score at the beginning of the control group before the study was 2.39 ± 2.18 and after 2.50 ± 2.30 (P = 0.078), with the result of the intervention group initially 2.15 ± 1.67 and after 3.98 ± 2.05 (p = 0.001) and Mo's adherence score in the intervention group 4.01 ± 1.84 and after 2.07 ± 1.32 (p = 0.001) and control group 3.80±1.84 and after 3.72±1.81 (p=0.2387) and 7 bleeding complications and 24 interactions in control and 7 with bleeding and 8 interactions in intervention group were found. Research findings conclude that pharmacist interventions play a role in anticlotting treatment to improve adherence and information improves quality of life.